Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 18/20 | 0.69 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28455718 | 0.94 | BRD4 (0.70) | BRD4 | |
| SCHEMBL22099674 | 0.93 | BRD4 (0.71) | BRD4 | |
| SCHEMBL17895249 | 0.85 | ALDH1A1 (0.51) | BRD4 | |
| SCHEMBL17895254 | 0.84 | BRD4 (0.50) | BRD4 | |
| SCHEMBL19786796 | 0.81 | BRD4 (0.59) | BRD4OPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL19771236 | 0.80 | BRD4 (0.61) | BRD4 | |
| SCHEMBL28466382 | 0.80 | BRD4 (0.66) | BRD4OPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL17895274 | 0.79 | BRD4 (0.54) | BRD4 | |
| SCHEMBL22099691 | 0.78 | BRD4 (0.43) | BRD4 | |
| SCHEMBL17895228 | 0.78 | BRD4 (0.56) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107454900-B | Novel imidazo [1,2-A ] quinoxalines and derivatives thereof for the treatment of cancer | 蒙彼利埃大学 | 2020-08-07 | — | — | CN | disclosed |
| US-10689384-B2 | Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer | UNIVERSITE DE MONTPELLIER (FR) | 2020-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689384-B2 | Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer | NQO1, NQO2, ABL1 | BRD4 222/4885OPRM1 1268/4885OPRD1 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.